Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 43

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 43
---
 of this prospectus                                                            
 for a discussion of factors to consider carefully before deciding to invest in our securities.                                               |
| Nasdaq symbol   |     | “NIVF” (Class A Ordinary Shares); “NIVFW” (Warrants to purchase Class A Ordinary Shares).                                                    |

The number of Ordinary Shares issued and outstanding is 2,152,702 as of September 15, 2025. No new Class A Ordinary Shares will be issued by us under this offering.

<div align='center'>24

RISK FACTORS</div>

Investing in our Class A Ordinary
Shares involves a high degree of risk. You should carefully consider the risks in this prospectus, the risk factors described under the
caption “Risk Factors” in any applicable prospectus supplement and any risk factors set forth in our other filings
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, before
making a decision about investing in our Class A Ordinary Shares. The risks and uncertainties we have described are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.
If any risks actually occur, our business, financial condition and results of operations may be materially and adversely affected. In
such an event, the trading price of our Class A Ordinary Shares could decline and you could lose part or all of your investment.

Additionally, we are also
subject to the following risk factors.

Risks Related to NewGenIvf’s Business and Industry

We may not be able to continue operating as a going concern.

As of December 31, 2024, the
Company’s cash and cash equivalents stood at approximately US$457,740. While the Company does not have immediate challenges to settle
its obligations when payments become due, the Company can make no assurance that it will have sufficient capital to bridge potential financial
and liquidity shortfalls.

The Company is always closely
monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company’s cash
flow position. As of April 10, 2025, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising
the Initial Note, the First Mandatory Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the
Company. A further US$